Our working capital at March 31, 2016 totaled approximately $14.0 million, including cash and short-term investments (comprised of government securities) of approximately $12.0 million. The Company has no debt.
Frederick H. Earnest, President and Chief Executive Officer, commented, "We continue to believe that our balance sheet will fund our currently planned activities into 2018.
"We are encouraged by the apparent renewed interest in the gold sector and the significant leverage that Vista stock has displayed relative to gold price changes.
a Fast Track SBIR grant !
Billions in revs.
Great for all oncology drugs !
This drug delivery system makes current oncology drugs more efficient. Kills the bad cells not the good. CELG would be my guess.
In Alzheimers alone it has shown 400% over SOC..Patients back to painting and golf and piano. I cant even play the piano!